[1]
|
Sun, H., Saeedi, P., Karuranga, S., et al. (2022) IDF Diabetes Atlas: Global, Regional and Country-Level Diabetes Prev-alence Estimates for 2021 and Projections for 2045. Diabetes Research and Clinical Practice, 183, 109-119.
https://doi.org/10.1016/j.diabres.2021.109119
|
[2]
|
Goh, G., Pan, A., Chow, W., et al. (2017) Association between Diabetes Mellitus and Cirrhosis Mortality: The Singapore Chinese Health Study. Liver International: Official Journal of the International Association for the Study of the Liver, 37, 251-258. https://doi.org/10.1111/liv.13241
|
[3]
|
Kisseleva, T. and Brenner, D. (2007) Role of Hepatic Stellate Cells in Fibro-genesis and the Reversal of Fibrosis. Journal of Gastroenterology and Hepatology, 22, S73-S78. https://doi.org/10.1111/j.1440-1746.2006.04658.x
|
[4]
|
Maruthur, N., Tseng, E., Hutfless, S., et al. (2016) Diabe-tes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-Analysis. Annals of Internal Medicine, 164, 740-751. https://doi.org/10.7326/M15-2650
|
[5]
|
Gangopadhyay, K. and Singh, P. (2017) Consensus Statement on Dose Modifications of Antidiabetic Agents in Patients with Hepatic Impairment. Indian Journal of Endocrinology and Metabo-lism, 21, 341-354.
https://doi.org/10.4103/ijem.IJEM_512_16
|
[6]
|
Singh, S., Singh, P., Singh, A., et al. (2013) Anti-Diabetic Medi-cations and the Risk of Hepatocellular Cancer: A Systematic Review and Meta-Analysis. The American Journal of Gas-troenterology, 108, 881-891; quiz 892.
https://doi.org/10.1038/ajg.2013.5
|
[7]
|
Brackett, C. (2010) Clarifying Metformin’s Role and Risks in Liver Dys-function. Journal of the American Pharmacists Association: JAPhA, 50, 407-410. https://doi.org/10.1331/JAPhA.2010.08090
|
[8]
|
Salpeter, S., Greyber, E., Pasternak, G., et al. (2003) Risk of Fatal and Nonfatal Lactic Acidosis with Metformin Use in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis. Archives of Internal Medicine, 163, 2594-2602.
https://doi.org/10.1001/archinte.163.21.2594
|
[9]
|
Khan, R., Foster, G. and Chowdhury, T. (2012) Managing Dia-betes in Patients with Chronic Liver Disease. Postgraduate Medicine, 124, 130-137. https://doi.org/10.3810/pgm.2012.07.2574
|
[10]
|
Lalau, J. and Race, J. (1999) Lactic Acidosis in Metformin-Treated Patients. Prognostic Value of Arterial Lactate Levels and Plasma Metformin Concentrations. Drug Safety, 20, 377-384.
https://doi.org/10.2165/00002018-199920040-00006
|
[11]
|
Lee, U. and Friedman, S. (2011) Mechanisms of Hepatic Fibrogenesis. Best Practice & Research Clinical Gastroenterology, 25, 195-206. https://doi.org/10.1016/j.bpg.2011.02.005
|
[12]
|
Wu, M., Xu, H., Liu, J., et al. (2021) Metformin and Fibrosis: A Review of Existing Evidence and Mechanisms. Journal of Diabetes Research, 2021, Article ID: 6673525. https://doi.org/10.1155/2021/6673525
|
[13]
|
Fan, K., Wu, K., Lin, L., et al. (2017) Metformin Mitigates Carbon Tet-rachloride-Induced TGF-β1/Smad3 Signaling and Liver Fibrosis in Mice. Biomedicine & Pharmacotherapy, 90, 421-426.
https://doi.org/10.1016/j.biopha.2017.03.079
|
[14]
|
Mccloskey, C., Cook, D., Kelly, B., et al. (2020) Metformin Abrogates Age-Associated Ovarian Fibrosis. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 26, 632-642.
https://doi.org/10.1158/1078-0432.CCR-19-0603
|
[15]
|
Evans, J., Donnelly, L., Emslie-Smith, A., et al. (2005) Metformin and Reduced Risk of Cancer in Diabetic Patients. BMJ (Clinical Research ed), 330, 1304-1305. https://doi.org/10.1136/bmj.38415.708634.F7
|
[16]
|
Lei, Y., Yi, Y., Liu, Y., et al. (2017) Metformin Targets Multi-ple Signaling Pathways in Cancer. Chinese Journal of Cancer, 36, 17. https://doi.org/10.1186/s40880-017-0184-9
|
[17]
|
Zhang, X., Harmsen, W., Mettler, T., et al. (2014) Continuation of Metformin Use after a Diagnosis of Cirrhosis Significantly Improves Survival of Patients with Diabetes. Hepatology (Baltimore, Md), 60, 2008-2016.
https://doi.org/10.1002/hep.27199
|
[18]
|
Kramer, J., Natarajan, Y., Dai, J., et al. (2022) Effect of Diabetes Medica-tions and Glycemic Control on Risk of Hepatocellular Cancer in Patients with Nonalcoholic Fatty Liver Disease. Hepa-tology (Baltimore, Md), 75, 1420-1428.
https://doi.org/10.1002/hep.32244
|
[19]
|
Hua, F., Yu, J. and Hu, Z. (2016) Diabetes and Cancer, Common Threads and Missing Links. Cancer Letters, 374, 54-61.
https://doi.org/10.1016/j.canlet.2016.02.006
|
[20]
|
Kosenko, E., Tikhonova, L., Alilova, G., et al. (2022) Is NMDA-Receptor-Mediated Oxidative Stress in Mitochondria of Peripheral Tissues the Essential Factor in the Pathogen-esis of Hepatic Encephalopathy? Journal of Clinical Medicine, 11, 827. https://doi.org/10.3390/jcm11030827
|
[21]
|
Ampuero, J., Ranchal, I., Nuñez, D., et al. (2012) Metformin Inhibits Glutaminase Activity and Protects against Hepatic Encephalopathy. PLOS ONE, 7, e49279. https://doi.org/10.1371/journal.pone.0049279
|
[22]
|
Alhaider, A., Korashy, H., Sayed-Ahmed, M., et al. (2011) Metformin Attenuates Streptozotocin-Induced Diabetic Nephropathy in Rats through Modulation of Oxidative Stress Genes Expression. Chemico-Biological Interactions, 192, 233-242. https://doi.org/10.1016/j.cbi.2011.03.014
|
[23]
|
Angeli, P., Garcia-Tsao, G., Nadim, M., et al. (2019) News in Pathophysiology, Definition and Classification of Hepatorenal Syndrome: A Step beyond the International Club of Asci-tes (ICA) Consensus Document. Journal of Hepatology, 71, 811-822. https://doi.org/10.1016/j.jhep.2019.07.002
|
[24]
|
Ginès, P., Solà, E., Angeli, P., et al. (2018) Hepatorenal Syndrome. Nature Reviews Disease Primers, 4, 23.
https://doi.org/10.1038/s41572-018-0022-7
|
[25]
|
De Franchis, R. (2015) Expanding Consensus in Portal Hyperten-sion: Report of the Baveno VI Consensus Workshop: Stratifying Risk and Individualizing Care for Portal Hypertension. Journal of Hepatology, 63, 743-752.
https://doi.org/10.1016/j.jhep.2015.05.022
|
[26]
|
Tripathi, D., Erice, E., Lafoz, E., et al. (2015) Metformin Reduces Hepatic Resistance and Portal Pressure in Cirrhotic Rats. American Journal of Physiology Gastrointestinal and Liver Physiology, 309, G301-309.
https://doi.org/10.1152/ajpgi.00010.2015
|
[27]
|
Yen, F., Huang, Y., Hou, M., et al. (2022) Metformin Use and Cir-rhotic Decompensation in Patients with Type 2 Diabetes and Liver Cirrhosis. British Journal of Clinical Pharmacology, 88, 311-322. https://doi.org/10.1111/bcp.14970
|
[28]
|
Eikawa, S., Nishida, M., Mizukami, S., et al. (2015) Im-mune-Mediated Antitumor Effect by Type 2 Diabetes Drug, Metformin. Proceedings of the National Academy of Scienc-es of the United States of America, 112, 1809-1814.
https://doi.org/10.1073/pnas.1417636112
|
[29]
|
Henderson, D., Frieson, D., Zuber, J., et al. (2017) Metformin Has Positive Therapeutic Effects in Colon Cancer and Lung Cancer. The American Journal of the Medical Sciences, 354, 246-251.
https://doi.org/10.1016/j.amjms.2017.05.006
|